Showing results (421-430 of 436) with videos related to
Sort By:
Pageof 44
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 24, 2024
Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assuranceJean Luc Prétet, Laila Sara Arroyo Mühr, Kate Cuschieri, et al.The Lancet Regional Health. Europe|February 3, 2026
European Code Against Cancer 5th edition: 14 ways you can help prevent cancerCarolina Espina, David Ritchie, Elio Riboli, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 12, 2025
The Human Papillomavirus (HPV) Laboratory e-Manual: A comprehensive guide for HPV testing and researchLaila Sara Arroyo Mühr, Carina Eklund, Camilla Lagheden, et al.Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsDarron R Brown, Susanne K Kjaer, Kristján Sigurdsson, et al.International Journal of Cancer|December 17, 2013
Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohortEsther Roura, Xavier Castellsagué, Michael Pawlita, et al.Pageof 44